Results 241 to 250 of about 1,696,282 (311)

Decoding the Pathophysiology of Autoimmune Diseases—Mechanism, Triggers, and Nanotherapeutics: A Review

open access: yesAdvanced NanoBiomed Research, EarlyView.
This review highlights how autoimmune diseases arise from intertwined immunological, genetic, and environmental factors, emphasizing gut microbiota dysbiosis as a pivotal driver. It outlines emerging nanotechnology‐based strategies—such as liposomes, hydrogels, and polymeric nanoparticles—that enhance targeted drug delivery, minimize systemic toxicity,
Md. Meraj Ansari   +5 more
wiley   +1 more source

A Multiepitope‐Based Lateral Flow Assay for Leprosy Antibodies

open access: yesAnalysis &Sensing, EarlyView.
An innovative lateral flow assay for leprosy diagnosis is based on gold nanoparticles and synthetic Mycobacterium leprae epitopes conjugated to keyhole limpet hemocyanin protein to enhance antibody detection. This strategy provides a rapid, accurate, and low‐cost approach for resource‐limited settings, enabling the early detection of infection. Leprosy
Cristiane Zocatelli‐Ribeiro   +7 more
wiley   +1 more source

T cell receptor clonotypes predict human leukocyte antigen allele carriage and antigen exposure history. [PDF]

open access: yesCommun Biol
ElAbd H   +6 more
europepmc   +1 more source

Chicken Pulmonary MicroRNAs Targeting the PB2 (Segment 1) of Avian Influenza Virus

open access: yesAnimal Research and One Health, EarlyView.
The PB2 segment of H5N1 is essential for replication and host adaptation. We screened 200 miRNAs and identified five (gga‐miR‐17‐3p, gga‐miR‐29a‐5p, gga‐miR‐1718, gga‐miR‐16c‐5p, and gga‐miR‐1744‐5p) using thermodynamic stability of heteroduplex, seed sequence complementarity, conservation, and accessibility, offering insights into host antiviral ...
Akanksha Choudhary   +7 more
wiley   +1 more source

A phase 2 trial of hydroxychloroquine in individuals at risk for rheumatoid arthritis

open access: yesArthritis &Rheumatology, Accepted Article.
Background Individuals with serum elevations of anti‐cyclic citrullinated peptide (anti‐CCP) antibodies are at increased risk for future rheumatoid arthritis (RA). No pharmacologic interventions have been approved for the prevention of RA in such ‘at‐risk’ individuals. However, hydroxychloroquine (HCQ) is used without supporting clinical trial evidence.
Kevin D. Deane   +33 more
wiley   +1 more source

Home - About - Disclaimer - Privacy